关于2018-2020年天然药物及仿生药物国家重点实验室大型技术平台建设的回顾与思考

doi:10.5246/jcps.2019.12.083

中国药学(英文版) ›› 2019, Vol. 28 ›› Issue (12): 878-884.DOI: 10.5246/jcps.2019.12.083

关于2018-2020年天然药物及仿生药物国家重点实验室大型技术平台建设的回顾与思考

宋书香^*

北京大学医学部药学院天然药物及仿生药物国家重点实验室, 北京 100191

收稿日期:2019-09-18 修回日期:2019-10-24 出版日期:2019-12-28 发布日期:2019-11-15
通讯作者: Tel.: +86-10-82805739, E-mail: shxsong@bjmu.edu.cn

Retrospect and reflection on the construction of large-scale technology platform of the State Key Laboratory of Natural and Biomimetic Drugs in 2018-2020

Shuxiang Song^*

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2019-09-18 Revised:2019-10-24 Online:2019-12-28 Published:2019-11-15
Contact: Tel.: +86-10-82805739, E-mail: shxsong@bjmu.edu.cn

摘要/Abstract

摘要：

天然药物及仿生药物国家重点实验室获批2018–2020年仪器设备专项经费近壹亿元, 创历史新高。围绕本室“天然产物复杂成分成药性的基础科学问题”和“内源性物质发挥治疗功能的仿生关键科学问题”两个大方向的科学研究, 开展科研仪器设备购置、试制、升级等方面的工作, 并配置高水平的技术和管理人员, 以解决在仪器设备方面制约重点实验室发展的瓶颈问题, 并努力保持我室上述两个传统方向的优势和引领作用。

关键词: 仪器平台建设, 优化资源配置, 服务科学研究

Abstract:

The State Key Laboratory of Natural and Biomimetic Drugs was approved for a funding of nearly 100 million yuan specifically aimed at the purchase and maintenance of equipment and instruments from 2018 to 2020, which is a record high. The Laboratory focuses on two major directions of scientific research, the “basic scientific problems of drug resistance of complex components of natural products” and the “key biomimetic scientific problems of endogenous substances therapeutic functions”. The selection of scientific instruments and equipment, trial production, upgrading, as well as high level of technical and managementpersonnel allocation and other aspects are critical to meet the development needs of the Key Laboratory and to maintain the advantages and leading role in these two major directions of scientific research.

Key words: Instrument platform construction, Optimization of resource allocation, Scientific research service

中图分类号:

Supporting:

宋书香. 关于2018-2020年天然药物及仿生药物国家重点实验室大型技术平台建设的回顾与思考[J]. 中国药学(英文版), 2019, 28(12): 878-884.

Shuxiang Song. Retrospect and reflection on the construction of large-scale technology platform of the State Key Laboratory of Natural and Biomimetic Drugs in 2018-2020[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(12): 878-884.

参考文献

[1] Zhou, D.M. Preface: Special issue on drug innovation driven by the integration of chemical biology of State Key Labortory of Natural and Biomimetic Drugs. Sci. Sin. Chim. 2018, 48, 1291-1292.

[2] Si, L.L.; Xu, H.; Zhou, X.Y.; Zhang, Z.W.; Tian, Z.Y.; Wang, Y.; Zhang, B.; Niu, Z.L.; Yao, T.; Li, S.; Zhang, C.L; Fu, G.; Xiao, S.L.; Xia, Q.; Zhang, L.H.; Zhou, D.M. Generation of Influenza A Viruses as Live but Replication-Incompetent Virus Vaccines. Science. 2016, 354, 1170-1173.

[3] Liu, J.Z; Qiu, X.; Huang, X.Q; Luo, X.; Zhang, C.; Wei, J.L.; Pan, J.; Liang, Y.J.; Zhu, Y.C; Qin, Q.X.; Song, S.; Jiao, N. From alkylarenes to anilines via site-directed carbon-carbon amination. Nat. Chem. 2019, 11, 71-77.

[4] Si, L.L.; Meng, K.; Tian, Z.Y.; Sun, J.Q.; Li, H.Q.; Zhang, Z.W.; Soloveva, V.; Li, H.W.; Fu, G.; Xia, Q.; Xiao, S.L.; Zhang, L.H.; Zhou, D.M. Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes. Sci. Adv. 2018, 4.

[5] Tang, H.T.; Dai, Z.; Qin, X.W.; Cai, W.K; Hu, L.M; Huang, Y.J.; Cao, W.B.; Yang, F.; Wang, C.; Liu, T. Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors. JACS. 2018, 140, 13253-13259.

[6] Li, L.; Yuan, K.; Jia, Q.L.; Jia, Y.X. Eight-Step Total Synthesis of Phalarine by Bioinspired Oxidative Coupling of Indole and Phenol. Angew. Chem-Int. Ed. 2019, 58, 6074-6078.

[7] Liao, L.X.; Song, X.M.; Wang, L.C.; Lv, H.N.; Chen, J.F.; Liu, D.; Fu, G.; Zhao, M.B.; Jiang, Y.; Zeng, K.W.; Tu, P.F. Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy. PNAS. 2017, 114, E5986-E5994.

[8] Wu, Y.; Xiong, D.C.; Chen, S.C.; Wang, Y.S.; Ye, X.S. Total synthesis of mycobacterial arabinogalactan containing 92 monosaccharide units. Nat. Commun. 2017, 8.

[9] Sun, L.; Wu, X.; Xiong, D.C.; Ye, X.S. Stereoselective Koenigs-Knorr Glycosylation Catalyzed by Urea. Angew. Chem-Int. Ed. 2016, 55, 8041-8044.

[10] Xiao, A.; Zheng, X.J.; Song, C.; Gui, Y.; Huo, C.X.; Ye, X.S. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines. Org. & Biomol. Chem. 2016, 14, 7226-7237.

[11] Liu, Y.; Lai, S.; Ma, W.; Ke, W.; Zhang, C.; Liu, S.; Zhang, Y.; Pei, F.; Li, S.; Yi, M.; Shu, Y.; Shang, Y.; Liang, J.; Huang, Z. CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression. Nat. Commun. 2017, 8.

[12] Lin, Z.H.; Liu, J.M.; Ding, H.D.; Xu, F.; Liu, H.L. Structural basis of SALM5-induced PTP delta dimerization for synaptic differentiation. Nat. Commun. 2018, 9.

[1]	林珅, 饶欣, 李逸元, 翁秀华, 王长连. 非鳞非小细胞肺癌患者二线化疗方案的成本-效果分析[J]. 中国药学(英文版), 2020, 29(8): 542-553.
[2]	谢程欣, 王维, 黄戈, 金鑫, 王成龙, 尹东. 中国药剂师干预减少骨科不合理用药的现状[J]. 中国药学(英文版), 2020, 29(6): 375-382.
[3]	聂玉瑶, 王贺, 周林光, 史录文, 江滨. 中国药师对仿制药认知的调查研究[J]. 中国药学(英文版), 2020, 29(5): 364-368.
[4]	宋书香. 国家重点实验室关于大型仪器设备采购控制过程探讨[J]. 中国药学(英文版), 2020, 29(3): 214-219.
[5]	聂智峰, 满春霞, 伊欣, 刘伊, 郭志刚, 管晓东, 史录文. 取消药品加成政策对57家县级公立医院医疗服务量的影响[J]. 中国药学(英文版), 2020, 29(3): 220-226.
[6]	周若婧, 江滨. 福建省药品联合限价阳光采购政策效果评估[J]. 中国药学(英文版), 2020, 29(2): 139-152.
[7]	周瑞瑞, 王利群, 孙桐, 吴紫阳, 谢晓慧. 三种不同的联用方案在中到极重度慢性阻塞性肺疾病患者中的有效性和安全性: 系统评价和meta分析[J]. 中国药学(英文版), 2019, 28(7): 502-518.
[8]	王壮飞, 管晓东, 周越, 韩晟, 姚鹏, 史录文. 中国中老年人自我药疗发生率及影响因素研究：基于CHARLS 2011年, 2013年和2015年的面板数据[J]. 中国药学(英文版), 2019, 28(6): 430-438.
[9]	杨东升, 马玲云, 牛剑钊, 许鸣镝. 美国授权仿制药应用简介[J]. 中国药学(英文版), 2019, 28(6): 439-445.
[10]	董志勇, 邱仙土, Stacy A. Kujawa, S.M. Shariful Islam, 张杰. 华蟾素注射液治疗中晚期原发性肝癌的统评价和Meta分析[J]. 中国药学(英文版), 2019, 28(4): 264-275.
[11]	陈敏, 姜锋, 郑铭, 阳丽梅, 高红瑾. 基于APICloud 的药物基因组用药指导信息的手机APP的设计与实现[J]. 中国药学(英文版), 2019, 28(4): 276-283.
[12]	张琪, 张博, 林能明. 基于伊马替尼治疗系统性硬化症疗效的meta分析[J]. 中国药学(英文版), 2019, 28(3): 195-202.
[13]	杨东升, 马玲云, 牛剑钊, 许鸣镝. 美国国家药品编码应用简介[J]. 中国药学(英文版), 2019, 28(3): 203-208.
[14]	卢新璞, 郭志刚, 傅孟元, 海沙尔江·吾守尔, 史录文, 管晓东. 中国基本药物制度对合理用药的影响: 基层医疗机构横断面研究[J]. 中国药学(英文版), 2019, 28(1): 49-55.
[15]	张弨, 谢若函, 王楚慧, 袭辰辰, 戈梦佳. 基于群体药动学和药效学的仿真对肾功能不全病人使用哌拉西林/他唑巴坦进行剂量优化[J]. 中国药学(英文版), 2018, 27(12): 824-831.

关于2018-2020年天然药物及仿生药物国家重点实验室大型技术平台建设的回顾与思考

Retrospect and reflection on the construction of large-scale technology platform of the State Key Laboratory of Natural and Biomimetic Drugs in 2018-2020

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价